Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
Scottish Medicines Consortium
Record ID 32018000968
English
Details
Project Status:
Completed
URL for project:
https://www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-full-smc2310/
Year Published:
2021
URL for published report:
https://www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-full-smc2310/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Scotland, United Kingdom
MeSH Terms
- Lymphoma, Large-Cell, Anaplastic
- Antibodies, Monoclonal, Humanized
- Antineoplastic Agents, Immunological
- Brentuximab Vedotin
- Antineoplastic Combined Chemotherapy Protocols
- Immunotoxins
Contact
Organisation Name:
Scottish Medicines Consortium (SMC)
Contact Address:
Delta House | 50 West Nile Street
Contact Name:
Susan Downie
Contact Email:
susan.downie3@nhs.scot
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.